TY - JOUR
T1 - Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters
AU - Lori, F.
AU - Rosenberg, E.
AU - Lieberman, J.
AU - Foli, A.
AU - Maserati, R.
AU - Seminari, E.
AU - Alberici, F.
AU - Walker, B.
AU - Lisziewicz, J.
PY - 1999/10/10
Y1 - 1999/10/10
N2 - Hydroxyurea and didanosine treatment suppressed HIV replication for more than 2 years, in the absence of viral breakthrough, in chronically infected patients. The profile of viral load reduction was unusual for a two-drug combination, since a continuous gradual decrease in viremia persisted despite residual viral replication. The increase in CD4+ T cell counts was not robust. However, unlike those of patients treated by other therapies, CD4+ T lymphocytes were functionally competent against HIV, mediating a vigorous HIV-specific helper T cell response in half of these patients. In addition, the percentages of naive CD4+ and CD8+ T lymphocytes were not different from those in uninfected individuals. These results demonstrate that prolonged antiretroviral therapy with a simple, well-tolerated combination of two affordable drugs can lead to sustained control of HIV, normalization of immune parameters, and specific anti-HIV immune response.
AB - Hydroxyurea and didanosine treatment suppressed HIV replication for more than 2 years, in the absence of viral breakthrough, in chronically infected patients. The profile of viral load reduction was unusual for a two-drug combination, since a continuous gradual decrease in viremia persisted despite residual viral replication. The increase in CD4+ T cell counts was not robust. However, unlike those of patients treated by other therapies, CD4+ T lymphocytes were functionally competent against HIV, mediating a vigorous HIV-specific helper T cell response in half of these patients. In addition, the percentages of naive CD4+ and CD8+ T lymphocytes were not different from those in uninfected individuals. These results demonstrate that prolonged antiretroviral therapy with a simple, well-tolerated combination of two affordable drugs can lead to sustained control of HIV, normalization of immune parameters, and specific anti-HIV immune response.
UR - http://www.scopus.com/inward/record.url?scp=0033544002&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033544002&partnerID=8YFLogxK
U2 - 10.1089/088922299310034
DO - 10.1089/088922299310034
M3 - Article
C2 - 10515148
AN - SCOPUS:0033544002
VL - 15
SP - 1333
EP - 1338
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
SN - 0889-2229
IS - 15
ER -